Journal of Nutrition Animal Diets/Enrichment Products...

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeppesen, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeppesen, P. B.

© 2003 The American Society for Nutritional Sciences J. Nutr. 133:3721-3724, November 2003


Symposium: Glucagon-Like Peptide 2: Function and Clinical Applications

Clinical Significance of GLP-2 in Short-Bowel Syndrome1

P. B. Jeppesen2

Department of Medicine CA-2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark

2To whom correspondence should be addressed. E-mail: Bekker{at}dadlnet.dk.

Although long-term parenteral nutrition is lifesaving in patients with intestinal failure, it is expensive, severely impairs the quality of life in the short-bowel patients and is associated with serious complications such as catheter sepsis, venous occlusions and liver disease. Therefore, treatments that aim to minimize intestinal absorption, thereby eliminating or minimizing the need for parenteral support, are needed. As a result, glucagon-like peptide 2 (GLP-2) has received attention. In this review, the nature of short-bowel syndrome is described and the antisecretory, transit modulating and intestinotrophic effects of GLP-2 are presented. As illustrated in a pilot study, GLP-2 may prove to be important in the attempt to optimize remnant intestinal function thereby eliminating the need for parenteral support and improving quality of life in short-bowel patients with intestinal failure.


KEY WORDS: • short-bowel syndrome • intestinal failure • intestinal adaptation • glucagon-like peptide 2.




This article has been cited by other articles:


Home page
J EndocrinolHome page
T. Jin
Mechanisms underlying proglucagon gene expression
J. Endocrinol., July 1, 2008; 198(1): 17 - 28.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. G. Burrin, B. Stoll, X. Guan, L. Cui, X. Chang, and D. Hadsell
GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets
Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E281 - E291.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
S J Middleton and N V Jamieson
The current status of small bowel transplantation in the UK and internationally
Gut, November 1, 2005; 54(11): 1650 - 1657.
[Full Text] [PDF]


Home page
J. Nutr.Home page
D. Burrin, X. Guan, B. Stoll, Y. M. Petersen, and P. T. Sangild
Glucagon-Like Peptide 2: A Key Link between Nutrition and Intestinal Adaptation in Neonates?
J. Nutr., November 1, 2003; 133(11): 3712 - 3716.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]